Login to Your Account


Biosimilars makers seek to defray U.S. risks

By Michael Fitzhugh
Staff Writer

Friday, June 27, 2014
SAN DIEGO – With an untested approval pathway for biosimilars in the U.S., industry intellectual property experts well versed in the world of small-molecule generics told BIO 2014 attendees that the best path for bringing follow-on biologics to market remains muddy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription